<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061098</url>
  </required_header>
  <id_info>
    <org_study_id>CEBAS-CSIC-4</org_study_id>
    <nct_id>NCT02061098</nct_id>
  </id_info>
  <brief_title>Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects</brief_title>
  <acronym>POMEcardio</acronym>
  <official_title>Effect of an Ellagitannin Rich Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects. A Double-blind, Cross-over, Dose-response, Randomized, Placebo-controlled Trial (The POMEcardio Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Scientific and Technological Research Council of Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators objective is to carry out a placebo-controlled, dose-response, randomized
      clinical trial to assess the effects of polyphenols or derived metabolites on cardiovascular
      disease risk in overweight adult subjects upon the consumption of pomegranate extract.

      The investigators hypothesis is that chronic consumption of a ellagitannin-rich source such
      as pomegranate extract could decrease serum oxidized-LDL as well as other inflammatory
      markers. The correlation between the effect exerted and the subjects' microbiota (capacity to
      produce the ellagitannin-derived metabolites urolithins) will indicate a possible role of
      urolithins on the effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum oxidized LDL-cholesterol concentration</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Effect on circulating levels of oxidized particles of LDL-cholesterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipids and lipoproteins levels</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Effects on serum total cholesterol, LDL-cholesterol, HDL-cholesterol and apolipoproteins A1 (ApoA1), B (ApoB) and E (ApoE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum sICAM, sVCAM and hsCRP</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Effect on soluble intercellular adhesion molecule (sICAM), soluble vascular adhesion molecule (sVCAM) and high-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal microbiota</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Prebiotic effect: Change in short fatty acids, bifidobacteria, lactobacilli and other selected species in feces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of volunteers with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Change in markers involved in hepatic and renal functions: GGT, AST, ALP, ALT, CPK, urate, creatinin, albumin, bilirubin, LDH.
Change in hematological variables: leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, mean corpuscular volume, mean platelet volume, platelets, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration.
Intolerance, dyspepsia, allergic reactions, constipation, diarrhea, abdominal pain, nausea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in phenolics and derived metabolites in plasma, feces and urine.</measure>
    <time_frame>Change from baseline at 3, 6, 9, 12, 15, 18, 21 and 24 weeks</time_frame>
    <description>Dose-response effect of pomegranate intake on phenolics and gut-microbiota derived metabolites in plasma, feces and urine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.
Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract-first dose-Group A</intervention_name>
    <description>Group A will consume 1 daily capsule of pomegranate extract for 3 weeks</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>Group A consumes pomegranate extract (first dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-first dose-Group B</intervention_name>
    <description>Group B will consume 1 daily capsules of placebo for 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group B consumes placebo (first dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract-first dose-Group B</intervention_name>
    <description>After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>Group B consumes pomegranate extract (first dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-first dose-Group A</intervention_name>
    <description>After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group A consumes placebo (first dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract-second dose-Group A</intervention_name>
    <description>After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>Group A consumes pomegranate extract (second dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-second dose-Group B</intervention_name>
    <description>After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group B consumes placebo (second dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract-second dose-Group B</intervention_name>
    <description>After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>Group B consumes pomegranate extract (second dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo-second dose-Group A</intervention_name>
    <description>After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group A consumes placebo (second dose)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 40-65 years

          -  Body mass index (BMI) &gt;27 kg/m2

          -  Healthy status (no illness in the previous 3-months).

        Exclusion Criteria:

          -  Smoking.

          -  Pregnancy/lactation.

          -  Severe medical illness/chronic disease/ or gastrointestinal pathology (ulcers,
             irritable bowel syndrome, ulcerative colitis, Crohn disease etc.).

          -  Previous gastrointestinal surgery

          -  Recent use of antibiotics (within 1-month prior to the study)

          -  Suspected hypersensitivity to pomegranate or any of its components

          -  Consumption of nutraceuticals, botanical extracts or other vitamin supplements or
             taking medication.

          -  Regular consumption of ellagitannin-containing foodstuffs (walnuts, pomegranate,
             strawberries, raspberries, oak-aged red wine) (after filling a food-frequency
             questionnaire).

          -  Intake of ellagitannins-containing foodstuffs the week before the pharmacokinetic
             intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Juan Carlos Espín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Council (CEBAS-CSIC, Murcia, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCAM (San Antonio Catholic University from Murcia)</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Council, Spain</investigator_affiliation>
    <investigator_full_name>Juan Carlos Espín de Gea</investigator_full_name>
    <investigator_title>Full Research Professor</investigator_title>
  </responsible_party>
  <keyword>Pomegranate</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Urolithins</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Nutraceutical</keyword>
  <keyword>Dietary supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

